Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cinqair

- PMLiVE

J&J responds to FDA concerns over Xarelto in ACS

Responds to regulator about missing clinical trial data

- PMLiVE

Lilly’s poor run continues as Alimta fails in lung cancer

Phase III trial comparing it to Roche's Avastin misses primary endpoint

FDA sued for approving high dose of Eisai’s Alzheimer’s drug Aricept

Consumer rights group Public Citizen claims the high-strength dose is unsafe

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

- PMLiVE

US drug approval numbers fall despite pharma investing more in R&D

Stricter FDA policies are partly to blame for the decline says GBI Research

- PMLiVE

Lilly launches branded app for emergency diabetes medicine

US-only Lilly Glucagon iPhone and iPad app shows carers how to use the hypoglycaemia treatment

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

Astellas wins US approval for prostate cancer drug Xtandi

Pharma company and its partner Medivation gain FDA licence for type of late-stage prostate cancer

- PMLiVE

Lilly appoints Michael Harrington SVP and general counsel

Replaces Robert Armitage who retires from the pharma company

Lilly drops touted Zyprexa successor for use in schizophrenia

Pomaglumetad methionil disappoints in phase III

- PMLiVE

Lilly’s Alzheimer’s drug solanezumab stumbles, but doesn’t fall in phase III

Fails to show significant benefit, but data holds some consolation

- PMLiVE

Interview: Jan Lundberg, Eli Lilly

We talk to Jan Lundberg, executive VP, science and technology, and president, Lilly Research Laboratories

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links